<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01149707</url>
  </required_header>
  <id_info>
    <org_study_id>PG09 PUR 0210 002</org_study_id>
    <secondary_id>2009 017839 18</secondary_id>
    <secondary_id>29PS1617</secondary_id>
    <nct_id>NCT01149707</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Efficacy Study of PUR 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative Colitis</brief_title>
  <official_title>A 2-Week Exploratory Randomized, Double-Blind, Parallel-Group, Dose-Ranging, Placebo-Controlled Safety, Tolerability, Biomarker and Efficacy Clinical Study of PUR 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PurGenesis Technologies Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PurGenesis Technologies Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PUR 0110 is a 100% natural novel investigational medicinal product that has been demonstrated&#xD;
      in several in vitro and in vivo pharmacology studies to have potent anti-inflammatory,&#xD;
      anti-oxidative and immunomodulatory effects. This exploratory Phase 2a study is a&#xD;
      first-in-patient study to evaluate the safety, tolerability, biomarker effect and efficacy of&#xD;
      PUR 0110 rectal enema in patients with active mild-to-moderate distal ulcerative colitis&#xD;
      (UC).&#xD;
&#xD;
      The study is a multicenter, randomized, double-blind, parallel-group, dose-ranging,&#xD;
      placebo-controlled study. To be eligible for inclusion into the study, patients must either&#xD;
      be newly diagnosed or have on-going active mild-to-moderate distal ulcerative colitis of at&#xD;
      least 3 months duration confirmed in either case by flexible sigmoidoscopy and biopsy at the&#xD;
      Screening Visit. In addition, patients must have a modified Mayo score of ≥5 to ≤10 including&#xD;
      a sigmoidoscopy inflammation grade and rectal bleeding scores of ≥2 each. Eligible patients&#xD;
      will be randomly assigned to receive either PUR 0110 250 mg, 500 mg or 1000 mg or placebo&#xD;
      rectal enema in a 1:1:1:1 ratio. Patients will self-administer the assigned study medication&#xD;
      intrarectally once-daily at bedtime (10:00 p.m +/- 1 hour) for 2 weeks.&#xD;
&#xD;
      Patients will be evaluated for safety by adverse events, clinical laboratory tests, vital&#xD;
      signs, physical examination, electrocardiogram (ECG), and concomitant medications. Efficacy&#xD;
      evaluations will include the modified Mayo score, patient-defined response and remission,&#xD;
      Investigator Assessment of Ulcerative Colitis Symptom Score, Inflammatory Bowel Disease&#xD;
      Questionnaire (IBDQ), and biomarkers of inflammation, apoptosis and total cell death, lipid&#xD;
      peroxidation and in vivo oxidative stress, and antioxidant defense mechanisms in plasma,&#xD;
      serum, urine, feces and biopsy tissue. Patients will have a flexible sigmoidoscopy and biopsy&#xD;
      12 hours after the last dose of study medication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety/Primary Outcome Parameters:&#xD;
&#xD;
        -  Incidence, nature and severity of adverse events&#xD;
&#xD;
        -  Incidence, nature and severity of clinical laboratory test abnormalities&#xD;
&#xD;
      Efficacy/Secondary Outcome Parameters:&#xD;
&#xD;
        -  Clinical remission defined as an endoscopy score of ≤ 1, a rectal bleeding score of 0,&#xD;
           and an improvement or no change from baseline in the stool frequency score at the end of&#xD;
           2 weeks of treatment / withdrawal visit;&#xD;
&#xD;
        -  Clinical response rate defined as the percentage of patients with a drop of ≥3 points&#xD;
           from the baseline overall modified Mayo score;&#xD;
&#xD;
        -  Patient defined response and remission rates;&#xD;
&#xD;
        -  Change from baseline in the overall modified Mayo score (Disease Activity Index);&#xD;
&#xD;
        -  Change from baseline in each of the 4 individual sub-scores of the modified Mayo score;&#xD;
&#xD;
        -  Change from baseline in Investigator Assessment of UC Symptom Score (total and&#xD;
           individual symptom scores)&#xD;
&#xD;
        -  Change from baseline in IBDQ score (total and the 4 individual dimension scores)&#xD;
&#xD;
        -  Proportion of patients with treatment failure;&#xD;
&#xD;
        -  Change from baseline in serum lutein levels;&#xD;
&#xD;
        -  Change from baseline in C-reactive protein (CRP), high sensitivity CRP (hs-CRP),&#xD;
           erythrocyte sedimentation rate (ESR), fecal calprotectin (FCP), and fecal lactoferrin&#xD;
           (FL).&#xD;
&#xD;
        -  Change from baseline in exploratory biomarkers including: serum interleukin-2 (IL-2),&#xD;
           IL-6, IL-8, interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-α),&#xD;
           transforming growth factor-beta (TGF-beta), IL-4, IL-10, IL-17, IL-23, human&#xD;
           beta-Defensin-2 (hBD-2), malondialdehyde (MDA), lipoxin A4 (LXA4), glutathione (GSH),&#xD;
           M30 and M65 apoptosomes in serum and biopsies, and plasma and urinary isoprostane&#xD;
           levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1, 2010</start_date>
  <completion_date type="Actual">June 20, 2015</completion_date>
  <primary_completion_date type="Actual">October 1, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with treatment-related adverse events</measure>
    <time_frame>At Week 2</time_frame>
    <description>Safety &amp; Tolerability of PUR0110 rectal enema compared to placebo as per Incidence, nature and severity of adverse events (AEs); and abnormal clinical laboratory test results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of PUR0110 on remission rate</measure>
    <time_frame>At week 2</time_frame>
    <description>Effectiveness of PUR0110 compared to placebo as per Clinical remission rate with clinical remission defined as an endoscopy score of ≤ 1, a rectal bleeding score of 0, and an improvement or no change from baseline in the stool frequency score at the end of 2 weeks of treatment / withdrawal visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of PUR0110 on clinical response rate</measure>
    <time_frame>At week 2</time_frame>
    <description>Effectiveness of PUR0110 compared to placebo as per : Clinical response rate defined as the percentage of subjects with a drop of ≥3 points from the baseline overall modified Mayo score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of PUR0110 on subject response and remission rate</measure>
    <time_frame>At week 2</time_frame>
    <description>Effectiveness of PUR0110 compared to placebo as per Subject defined response and remission rates based on their well being : 1= much better; 2= some better; 3=a little better; 4= about the same; 5=a little worse; 6= some worse &amp; 7= much worse.ed as : o= none; 1 = mild; 2=moderate, 3=severe and 4 = incapacitating.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of PUR0110 on overall Mayo score</measure>
    <time_frame>At week 2</time_frame>
    <description>Effectiveness of PUR0110 compared to placebo as per Change from baseline in the overall modified Mayo score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of PUR0110 on in each of the 4 individual sub-scores of the modified Mayo score.</measure>
    <time_frame>At week 2</time_frame>
    <description>Effectiveness of PUR0110 compared to placebo as per Change from baseline in each of the 4 individual sub-scores of the modified Mayo score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of PUR0110 on investigator assessment of ulcerative colitis symptom score</measure>
    <time_frame>At week 2</time_frame>
    <description>Effectiveness of PUR0110 compared to placebo as per Change from baseline in investigator assessment of ulcerative colitis symptom score : 0= none; 1= Mild; 2=Moderate; 3=Severe and 4 = incapacitating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of PUR0110 on inflammatory bowel disease questionnaire (IBDQ) score</measure>
    <time_frame>At week 2</time_frame>
    <description>Effectiveness of PUR0110 compared to placebo as per Change from baseline in inflammatory bowel disease questionnaire (IBDQ) score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of PUR0110 on proportion of subjects with treatment failure defined as unchanged, worsened or missing modified Mayo score</measure>
    <time_frame>At week 2</time_frame>
    <description>Effectiveness of PUR0110 compared to placebo as per : Proportion of subjects with treatment failure;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of PUR0110 on biomarkers of inflammation</measure>
    <time_frame>At week 2</time_frame>
    <description>Change from baseline in exploratory biomarkers - serum IL-2, IL-6, IL8, IFN-γ, TNF-α, TGF-β, IL-4, IL-10, IL-17, IL-23, hβD-2, MDA, LXA4, GSH and LTB4 levels in serum and biopsies; plasma and urinary isoprostane levels and serum lipoxin A4 levels..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of PUR0110 on C-reactive Protein (CRP), high sensitivity CRP (hsCRP), erythrocyte sedimentation rate (ESR), Fecal Falprotectin (FCP) and Fecal Lactoferrin (FL) compared to placebo</measure>
    <time_frame>At week 2</time_frame>
    <description>Change from baseline in CRP, hs-CRP, ESR, FCP and FL .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of PUR0110 on M30 apoptosome in serum and biopsies</measure>
    <time_frame>At week 2</time_frame>
    <description>Effect of PUR0110 on M30 apoptosome in serum and biopsies compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of PUR0110 on M65 apoptosome in serum and biopsies</measure>
    <time_frame>At week 2</time_frame>
    <description>Effect of PUR0110 on M65 apoptosome in serum and biopsies compared to placebo</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Left-Sided Ulcerative Colitis</condition>
  <condition>Proctosigmoiditis</condition>
  <arm_group>
    <arm_group_label>PUR 0110 Rectal Enema 250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PUR 0110 Rectal Enema 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PUR 0110 Rectal Enema 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Enema</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PUR 0110 Rectal Enema 250 mg</intervention_name>
    <description>PUR 0110 Rectal Enema 250 mg, once-daily, intrarectally</description>
    <arm_group_label>PUR 0110 Rectal Enema 250 mg</arm_group_label>
    <other_name>Active treatment arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PUR 0110 Rectal Enema 500 mg</intervention_name>
    <description>PUR 0110 Rectal Enema 500 mg, once-daily, intrarectally</description>
    <arm_group_label>PUR 0110 Rectal Enema 500 mg</arm_group_label>
    <other_name>Active treatment arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PUR 0110 Rectal Enema 1000 mg</intervention_name>
    <description>PUR 0110 Rectal Enema 1000 mg, once-daily, intrarectally</description>
    <arm_group_label>PUR 0110 Rectal Enema 1000 mg</arm_group_label>
    <other_name>Active treatment arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Enema</intervention_name>
    <description>Placebo Enema, once-daily, intrarectally</description>
    <arm_group_label>Placebo Enema</arm_group_label>
    <other_name>Placebo arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Outpatient males and females between 18 and 75 years.&#xD;
&#xD;
          2. Females of child bearing potential must have a negative serum pregnancy test&#xD;
             (beta-human chorionic gonadotropin) at screening and must be sexually inactive&#xD;
             (abstinent) for 3 months prior to dosing and throughout the study or be using one of&#xD;
             the following acceptable methods of contraception:&#xD;
&#xD;
               -  barrier methods (condom, diaphragm with spermicide);&#xD;
&#xD;
               -  Intrauterine device (IUD) in place for at least 3 months;&#xD;
&#xD;
               -  surgical sterilization of the partner (vasectomy for at least 6 months); or&#xD;
&#xD;
               -  hormonal contraceptives for at least 3 months prior to dosing. [Female subjects&#xD;
                  of childbearing potential must be advised to remain sexually inactive or maintain&#xD;
                  the same method of contraception for ≥7 days following the end of dosing of study&#xD;
                  treatment]&#xD;
&#xD;
          3. Patients newly diagnosed or with ongoing active distal ulcerative colitis of &gt;3 months&#xD;
             duration, confirmed by flexible sigmoidoscopy during screening, and extending 5 to 50&#xD;
             cm from the anal margin. Sigmoidoscopy must be conducted within not more than 3 +/- 1&#xD;
             days before the Baseline (Day 0) Visit.&#xD;
&#xD;
          4. Patients with ongoing active distal ulcerative colitis of ≥3 months duration must be&#xD;
             on a stable dose of oral mesalamine (5-ASA) for ≥2 months before the Baseline (Day 0)&#xD;
             Visit.&#xD;
&#xD;
          5. Modified Mayo Score (Disease Activity Index) of ≥5 to ≤10 at Baseline, including a&#xD;
             sigmoidoscopic inflammation grade score of ≥2 and a rectal bleeding score ≥2.&#xD;
&#xD;
          6. Negative stool test at screening to rule out parasites, bacterial pathogens and&#xD;
             Clostridium difficile.&#xD;
&#xD;
          7. Able and willing to fill in (maintain) daily diary cards from Day -7 to Day 21 of the&#xD;
             study.&#xD;
&#xD;
          8. Able to provide voluntary written informed consent prior to initiation of screening,&#xD;
             must be capable of following the verbal and written study instructions, and be able to&#xD;
             commit to the return visits during the entire period of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of clinically significant cardiovascular, pulmonary, hepatic,&#xD;
             renal, hematological, gastrointestinal, endocrine, immunologic, dermatological,&#xD;
             neurological, or psychiatric disease, that could compromise patient's ability to&#xD;
             participate in the study, and/or interfere with absorption of the study drug or the&#xD;
             interpretation of the study data.&#xD;
&#xD;
          2. Patients with a diagnosis of Crohn's disease.&#xD;
&#xD;
          3. Patients with a modified Mayo score of ≥11 at the Screening (Day -7 &amp; Day -3) Visits.&#xD;
&#xD;
          4. Patients at immediate or significant risk of toxic megacolon; those with bowel&#xD;
             stricture, colonic dysplasia, adenoma or carcinoma.&#xD;
&#xD;
          5. Use of botanical treatments and supplements for ulcerative colitis within 14 days&#xD;
             prior to the Baseline Visit.&#xD;
&#xD;
          6. Patients with any enteric pathogens, ova or parasites, or Clostridium difficile toxin&#xD;
             in stool.&#xD;
&#xD;
          7. Female patients with a positive pregnancy test or lactating at the Screening/Baseline&#xD;
             Visits.&#xD;
&#xD;
          8. History of allergic reaction or hypersensitivity to spinach, spinach tablet, spinach&#xD;
             powder or spinach extract; and to latex, molds and mushrooms.&#xD;
&#xD;
          9. History of gout, pseudogout or hyperuricemia, or kidney stones.&#xD;
&#xD;
         10. History of pseudoallergic hypersensitivity to the food color additives, tartrazine&#xD;
             (E102), sunset yellow (E110) and FD &amp; C Blue No.1 (Brilliant blue FCF; E133), allergic&#xD;
             asthma, aspirin intolerance, and severe or multiple allergies.&#xD;
&#xD;
         11. Past medical history of significant gastrointestinal surgery including but not limited&#xD;
             to colostomy, ileostomy, or previous colonic surgery other than appendectomy.&#xD;
&#xD;
         12. Patients with anatomical abnormalities of the colon, e.g., short bowel or other&#xD;
             abnormalities.&#xD;
&#xD;
         13. Patients with any current infectious, ischemic, or immunologic disease with&#xD;
             gastrointestinal involvement.&#xD;
&#xD;
         14. Patients with a history of failure to retain enemas.&#xD;
&#xD;
         15. Use of antibiotics for reasons related to the primary diagnosis or for other&#xD;
             gastrointestinal-related conditions within 14 days of Baseline Visit.&#xD;
&#xD;
         16. Patients who used non-steroidal anti-inflammatory drugs (NSAIDs), including&#xD;
             cyclooxygenase-2 (COX-2) inhibitors, within 14 days prior to Baseline Visit. Except&#xD;
             aspirin ≤325 mg/day for cardiovascular prophylaxis.&#xD;
&#xD;
         17. Patients who used the following medications used for treating ulcerative colitis from&#xD;
             the times indicated below to the end of Week 3 (Visit 6):&#xD;
&#xD;
               -  Topical intrarectal corticosteroids or topical intrarectal mesalamine within 14&#xD;
                  days of Baseline Visit;&#xD;
&#xD;
               -  Systemic corticosteroids (oral or injectable, including adrenocorticotropic&#xD;
                  hormone [ACTH]) within 30 days of Baseline Visit;&#xD;
&#xD;
               -  Immunosuppressant therapy (methotrexate, azathioprine, 6-mercatopurine or&#xD;
                  cyclosporine) within 60 days of Baseline Visit; and&#xD;
&#xD;
               -  Biologic therapy (tumor necrosis factor-α inhibitors, monoclonal antibodies,&#xD;
                  etc.) within 90 days of Baseline Visit.&#xD;
&#xD;
         18. Patients with a history of active malignancy within the past 5 years except for&#xD;
             squamous cell or basal cell cancers of the skin.&#xD;
&#xD;
         19. History of any clinical laboratory abnormality deemed significant by the Principal&#xD;
             Investigator.&#xD;
&#xD;
         20. History of significant alcohol or drug abuse within one year prior to the Screening&#xD;
             Visit.&#xD;
&#xD;
         21. Patients who tested positive at Screening for human immunodeficiency virus (HIV),&#xD;
             hepatitis B surface antigen (HbsAg) or hepatitis C virus (HCV).&#xD;
&#xD;
         22. Exposure to any investigational or non-registered drug within 30 days prior to&#xD;
             administration of study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theophilus J Gana, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Devonian Health Group Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Rünzi, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Essen-Werden, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PurGenesis Investigational Site</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PurGenesis Investigational Site</name>
      <address>
        <city>Köln-Merheim</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PurGenesis Investigational Site</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PurGenesis Investigational Site</name>
      <address>
        <city>Minden</city>
        <zip>32423</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PurGenesis Investigational Site</name>
      <address>
        <city>Oelde</city>
        <zip>59302</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PurGenesis Investigational Site</name>
      <address>
        <city>Werden</city>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>June 22, 2010</study_first_submitted>
  <study_first_submitted_qc>June 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2010</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PUR 0110</keyword>
  <keyword>PUR 0110 Rectal Enema</keyword>
  <keyword>Distal Ulcerative Colitis</keyword>
  <keyword>Left-Sided Ulcerative Colitis</keyword>
  <keyword>Mild</keyword>
  <keyword>Moderate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Proctocolitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

